COMP
Cartilage oligomeric matrix protein
Also known as: COMP_HUMAN, EDM1, EPD1, MED, PSACH, THBS5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P49747
- Gene
- COMP
- Ensembl
- ENSG00000105664
- Chromosome
- 19
- Canonical length
- 757 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Golgi apparatus
- Secretome location
- Secreted to extracellular matrix
OverviewNCBI Gene
The protein encoded by this gene is a noncollagenous extracellular matrix (ECM) protein. It consists of five identical glycoprotein subunits, each with EGF-like and calcium-binding (thrombospondin-like) domains. Oligomerization results from formation of a five-stranded coiled coil and disulfides. Binding to other ECM proteins such as collagen appears to depend on divalent cations. Contraction or expansion of a 5 aa aspartate repeat and other mutations can cause pseudochondroplasia (PSACH) and multiple epiphyseal dysplasia (MED). [provided by RefSeq, Jul 2016]
Canonical amino-acid sequenceUniProt
757 residues, UniProt reviewed canonical sequence.
>P49747|COMP
1 MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRE LLRQQVREIT
61 FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGAR CGPCPAGFTG
121 NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD
181 INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRRAQRFCP DGSPSECHEH
241 ADCVLERDGS RSCVCAVGWA GNGILCGRDT DLDGFPDEKL RCPERQCRKD NCVTVPNSGQ
301 EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK
361 DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD
421 VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS
481 RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD
541 PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI
601 FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT
661 ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG
721 RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQALocalizationUniProt · AlphaFold · HPA
Whether an antibody against COMP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 334 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 334 nTPM
- skin: 78 nTPM
- adipose tissue: 73 nTPM
- heart muscle: 62 nTPM
- vagina: 22 nTPM
- skeletal muscle: 18 nTPM
Single-cell type
- epididymal basal cells: 206 nCPM
- late spermatids: 149 nCPM
- fibroblasts: 76 nCPM
- endometrial glandular cells: 62 nCPM
- late primary spermatocytes: 57 nCPM
- early spermatids: 35 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebellum: 2.8 nTPM
- spinal cord: 0.8 nTPM
- basal ganglia: 0.6 nTPM
- medulla oblongata: 0.6 nTPM
- cerebral cortex: 0.5 nTPM
- white matter: 0.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about COMP.
Disease | AllUniProt
Conditions COMP is implicated in, by any mechanism.
- Multiple epiphyseal dysplasia 1 (EDM1) MIM:132400
- Pseudoachondroplasia (PSACH) MIM:177170
- Carpal tunnel syndrome 2 (CTS2) MIM:619161
Disease | GeneticClinVar
174 pathogenic / likely-pathogenic of 892 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Pseudoachondroplastic spondyloepiphyseal dysplasia syndrome
- Multiple epiphyseal dysplasia type 1
- COMP-related disorder
- Multiple epiphyseal dysplasia
- Carpal tunnel syndrome 2
Disease | ImmuneIEDB
Conditions an epitope on COMP was assayed in.
- rheumatoid arthritis B cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against COMP are reported. Each links to that disease's full target list.
Showing 0 of 1 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for COMP from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Antibodies to Cartilage Oligomeric Matrix Protein Are Pathogenic in Mice and May Be Clinically Relevant in Rheumatoid Arthritis.
2022 · Arthritis Rheumatol · RCR 1.5 · 14 citations - Persistent high serum levels of cartilage oligomeric matrix protein in a subgroup of patients with traumatic knee injury.
1998 · Rheumatol Int · RCR 1.1 · 35 citations - Cartilage oligomeric matrix protein specific antibodies are pathogenic.
2012 · Arthritis Res Ther · RCR 0.6 · 20 citations - Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein.
2001 · J Immunol · RCR 0.4 · 20 citations - Incomplete B cell tolerance to cartilage oligomeric matrix protein in mice.
2013 · Arthritis Rheum · RCR 0.1 · 4 citations
Show 1 more
- (Auto)immunity to cartilage matrix proteins - a time bomb?
2013 · Arthritis Res Ther · RCR 0.1 · 4 citations
Reference: B cellIEDB
1 publication
- Antibodies to Cartilage Oligomeric Matrix Protein Are Pathogenic in Mice and May Be Clinically Relevant in Rheumatoid Arthritis.
2022 · Arthritis Rheumatol · RCR 1.5 · 14 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.77
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.78
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- animal organ morphogenesis
- apoptotic process
- artery morphogenesis
- BMP signaling pathway
- bone mineralization
- cartilage homeostasis
- cellular senescence
- chondrocyte development
- chondrocyte proliferation
- collagen fibril organization
- growth plate cartilage development
- limb development
- multicellular organism growth
- musculoskeletal movement
- negative regulation of apoptotic process
- platelet aggregation
- positive regulation of chondrocyte proliferation
- protein homooligomerization
- protein processing
- protein secretion
- regulation of bone mineralization
- regulation of gene expression
- response to unfolded protein
- skeletal system development
- skin development
- tendon development
- vascular associated smooth muscle cell development
- vascular associated smooth muscle contraction
- negative regulation of hemostasis
Molecular functions
- BMP binding
- calcium ion binding
- collagen binding
- extracellular matrix structural constituent
- heparan sulfate proteoglycan binding
- heparin binding
- integrin binding
- protease binding
- proteoglycan binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-like domain
- EGF-like calcium-binding domain
- Thrombospondin, type 3-like repeat
- Thrombospondin, C-terminal
- Growth factor receptor cysteine-rich domain superfamily
- Concanavalin A-like lectin/glucanase domain superfamily
- Thrombospondin, type 3 repeat
- EGF-like calcium-binding, conserved site
- Thrombospondin/cartilage oligomeric matrix protein, coiled-coil domain
- TSP type-3 repeat
- TSP/COMP, coiled-coil domain superfamily
- NOTCH1, EGF-like calcium-binding domain
- Thrombospondin type 3 repeat
- Thrombospondin C-terminal region
- Calcium-binding EGF domain
- Cartilage oligomeric matrix protein
- Thrombospondin-5, coiled coil domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of COMP in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads COMP as an antibody target. Whether an autoantibody or antibody against COMP could matter depends on whether native COMP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
COMP is annotated as secreted, so native COMP circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label COMP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...